Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Revenue

In the fiscal year ending March 31, 2026, Cohance Lifesciences had annual revenue of 22.69B INR, down -13.03%. Cohance Lifesciences had revenue of 6.19B in the quarter ending March 31, 2026, a decrease of -26.33%.

• Revenue: 22.69B
• Revenue Growth: -13.03%
• P/S Ratio: 6.84
• Revenue / Employee: 18.72M
• Employees: 1,212
• Market Cap: 155.26B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	22.69B	-3.40B	-13.03%
Mar 31, 2025	26.09B	15.57B	148.11%
Mar 31, 2024	10.51B	-2.89B	-21.56%
Mar 31, 2023	13.40B	201.07M	1.52%
Mar 31, 2022	13.20B	3.11B	30.75%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 18, 2026

Data Sources Report a data error